New drugs for the treatment of pancreatic cancer

Share This Post

Ruiwen Zhang and Robert L. Boblitt from the University of Houston have developed a new pancreatic cancer drug. The research was published in the Journal of Cancer Research. The drug targets two genes at the same time, and this breakthrough achievement is of great significance for the treatment of aggressive and deadly pancreatic cancer.

The drug is also expected to become a framework for the development of drugs to treat other forms of cancer or other diseases. Pancreatic cancer occurs when pancreatic cells begin to multiply out of control and develop into lumps, and the resulting cancer cells can invade other parts of the body. Most cancers start in the area of ​​the pancreas that produces digestive enzymes. Symptoms include back or stomach pain, unexpected weight loss, and jaundice (yellow skin). In addition, a person’s urine may appear dark yellow and itchy skin. There are two oncogenes associated with pancreatic cancer. There are two main ways for the drug to inhibit pancreatic cancer. They activate the nuclear factor of T cell 1 (NFAT1) and murine double microparticle 2 (MDM2), respectively. The latter gene regulates a tumor suppressor gene called p53. When there is no tumor suppressor p53, MDM2 can cause cancer. NFAT1 is used to up-regulate the expression of MDM2, thereby promoting tumor growth. Factors related to diet, nutrition and the environment can lead to increased levels of these factors in the cell.

When talking about this discovery, Dr. Zhang said that the clinical needs of new, effective and safe drugs for the treatment of pancreatic cancer have not yet been met. Our findings represent a major advancement in cancer research. He added: “Most drugs only target one factor. We identified a compound that targets two cancer-related genes. “The new drug is a synthetic compound of MA242. The drug can consume two proteins at the same time, thereby improving the tumor killing efficiency.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Risk of developing secondary tumors following CAR-T cell therapy is minimal - A Stanford Study
CAR T-Cell therapy

Risk of developing secondary tumors following CAR-T cell therapy is minimal – A Stanford Study

CAR-T cell therapy, a groundbreaking cancer treatment, carries a risk of developing secondary tumors. This occurs due to the therapy’s potential to cause genetic mutations or alter the immune system’s regulation. Secondary malignancies can arise from these changes, presenting a significant long-term risk for patients. Continuous monitoring and research are crucial to understanding and mitigating these risks, ensuring safer outcomes for those undergoing CAR-T cell therapy.

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients
CAR T-Cell therapy

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital is launching a groundbreaking CAR T-cell clinical trial for pediatric lupus patients. This innovative approach harnesses the body’s immune cells to target and eliminate lupus-affected cells, offering new hope for young patients with this autoimmune disorder. The trial represents a significant advancement in lupus treatment, aiming to improve outcomes and reduce long-term complications for children suffering from this challenging condition.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy